SanBio Primary Researcher Receives 2017 Smithsonian American Ingenuity Award

  SanBio Primary Researcher Receives 2017 Smithsonian American Ingenuity Award

 Dr. Gary Steinberg recognized for promising research with SanBio’s stem cell
                                   therapy

Business Wire

MOUNTAIN VIEW, Calif. -- January 4, 2018

SanBio, Inc., a leader in regenerative cell therapies for neurological
disorders, joins the Smithsonian Institution in recognizing Stanford
University’s Dr. Gary Steinberg, chair of neurosurgery, for his pioneering
research in the treatment of stroke patients. Steinberg received the
Smithsonian’s prestigious American Ingenuity Award in Life Sciences for his
unrelenting and unconventional approach to helping stroke patients regain
motor function. Steinberg was the primary investigator in SanBio’s Phase 1/2a
clinical trial in which stroke patients receiving SB623 demonstrated
clinically significant improvement in motor function.

Said Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio,
“This well-deserved recognition of Dr. Steinberg’s exemplary career and
ongoing research shines light on the potential of stem cell therapies like
SB623 to treat patients suffering from chronic physical impairments following
a stroke.”

Dr. Steinberg was honored in the Life Sciences category for his commitment to
neurological research and stroke patients. He also received recognition in
Smithsonian magazine.

About SanBio, Inc. (SanBio)
SanBio is a regenerative medicine company headquartered in Tokyo, Japan, and
Mountain View, California, with cell-based products in various stages of
research, development, and clinical trials. Its proprietary cell-based
product, SB623, is currently in a Phase 2b clinical trial for treatment of
chronic motor impairments resulting from stroke with its joint development
partner, Sumitomo Dainippon Pharma Co., Ltd., in the United States and Canada.
SanBio is also implementing a global Phase 2 clinical trial in the United
States and Japan using SB623 for treatment of motor impairment resulting from
traumatic brain injury. More information about SanBio, Inc. is available at
http://sanbio.com.

View source version on businesswire.com:
http://www.businesswire.com/news/home/20180104005262/en/

Contact:

For SanBio, Inc.
Kris Patrow, 612-455-1748
Kris.Patrow@PadillaCo.com
Press spacebar to pause and continue. Press esc to stop.